Improved neutralizing antibody response in the second season after a single dose of pandemic (H1N1) 2009 influenza vaccine in HIV-1-positive adults

Vaccine

Volumn 30, Issue 26, 2012, Pages 3819-3823

  Kikuchi, Tadashi ^a   Iwatsuki Horimoto, Kiyoko ^b   Adachi, Eisuke ^a   Koga, Michiko ^a   Nakamura, Hitomi ^a   Hosoya, Noriaki ^a   Kawana Tachikawa, Ai ^a   Koibuchi, Tomohiko ^a   Miura, Toshiyuki ^a,e,f   Fujii, Takeshi ^a   Kawaoka, Yoshihiro ^b,c,d   Iwamoto, Aikichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b THE UNIVERSITY OF TOKYO   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e VIIV HEALTHCARE   (United States)

^f NAGASAKI UNIVERSITY   (Japan)

Author keywords

HIV; Pandemic (H1N1) 2009 influenza

Indexed keywords

INFLUENZA VACCINE; NEUTRALIZING ANTIBODY;

2009 H1N1 INFLUENZA; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; INFLUENZA VACCINATION; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEASONAL INFLUENZA; SINGLE DRUG DOSE; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; JAPAN; MALE; MIDDLE AGED;

EID: 84861125784     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.083     Document Type: Article

References (22)

1. Itoh Y., Shinya K., Kiso M., Watanabe T., Sakoda Y., Hatta M., et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009, 460(August (7258)):1021-1025.
2. Bautista E., Chotpitayasunondh T., Gao Z., Harper S.A., Shaw M., Uyeki T.M., et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. The New England Journal of Medicine 2010, 362(May (18)):1708-1719.
3. Bickel M., Wieters I., Khaykin P., Nisius G., Haberl A., Stephan C., et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 2010, 24(June (9)):F31-F35.
4. Tebas P., Frank I., Lewis M., Quinn J., Zifchak L., Thomas A., et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS 2010, 24(September (14)):2187-2192.
5. Crum-Cianflone N.F., Eberly L.E., Duplessis C., Maguire J., Ganesan A., Faix D., et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clinical Infectious Diseases 2011, 52(January (1)):138-146.
6. Yanagisawa N., Maeda K., Ajisawa A., Imamura A., Suganuma A., Ando M., et al. Reduced immune response to influenza A (H1N1) 2009 monovalent vaccine in HIV-infected Japanese subjects. Vaccine 2011, 29(August (34)):5694-5698.
7. Hatakeyama S., Iwatsuki-Horimoto K., Okamoto K., Nukui Y., Yata N., Fujita A., et al. Unadjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected adults. Vaccine 2011, 29(November (49)):9224-9228.
8. Tiu C.T., Lin Y.S., Pagala M., Ghitan M., Treanor J.J., Fitzgerald T., et al. Antibody response to inactivated influenza A (H1N1) 2009 monovalent vaccine in patients with and without HIV. Journal of Acquired Immune Deficiency Syndrome 2011, 58(November (3)):e99-e102.
9. Palma P., Romiti M.L., Bernardi S., Pontrelli G., Mora N., Santilli V., et al. Safety and immunogenicity of a monovalent MF59((R))-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults. Biologicals 2012, (January).
10. Fabbiani M., Di Giambenedetto S., Sali M., Farina S., Sansonetti P., Tamburrini E., et al. Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. Vaccine 2011, 29(April (16)):2836-2839.
11. Manuel O., Pascual M., Hoschler K., Giulieri S., Alves D., Ellefsen K., et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clinical Infectious Diseases 2011, 52(January (2)):248-256.
12. Kajaste-Rudnitski A., Galli L., Nozza S., Tambussi G., Di Pietro A., Pellicciotta G., et al. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1 v influenza vaccine in HIV-1-infected individuals. AIDS 2011, 25(January (2)):177-183.
13. Launay O., Desaint C., Durier C., Loulergue P., Duval X., Jacomet C., et al. Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. Journal of Infectious Diseases 2011, 204(Juny (1)):124-134.
14. Pariani E., Boschini A., Amendola A., Poletti R., Anselmi G., Begnini M., et al. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. Vaccine 2011, 29(November (49)):9209-9213.
15. Soonawala D., Rimmelzwaan G.F., Gelinck L.B., Visser L.G., Kroon F.P. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS ONE 2011, 6(1):e16496.
16. Cagigi A., Nilsson A., Pensieroso S., Chiodi F. Dysfunctional B-cell responses during HIV-1 infection: implication for influenza vaccination and highly active antiretroviral therapy. The Lancet Infectious Diseases 2010, 10(July (7)):499-503.
17. Bickel M., von Hentig N., Wieters I., Khaykin P., Nisius G., Haberl A., et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clinical Infectious Diseases 2011, 52(January (1)):122-127.
18. World Health Organization. Dept. of Epidemic and Pandemic Alert and Response. WHO manual on animal influenza diagnosis and surveillance. Geneva: World Health Organization; 2002.
19. Iwatsuki-Horimoto K., Horimoto T., Tamura D., Kiso M., Kawakami E., Hatakeyama S., et al. Seroprevalence of pandemic 2009 (H1N1) influenza A virus among schoolchildren and their parents in Tokyo, Japan. Clinical and Vaccine Immunology 2011, 18(May (5)):860-866.
20. Pang X., Yang P., Li S., Zhang L., Tian L., Li Y., et al. Pandemic (H1N1) 2009 among quarantined close contacts, Beijing, People's Republic of China. Emerging Infectious Diseases 2011 Oct, 17(October (10)):1824-1830.
21. Tokyo-to Influenza Jouhou (Japanese), Tokyo Metropolitan Institute of Public Health. 2011 [cited 2012 Feb. 27]; Available from: http://idsc.tokyo-eiken.go.jp/.
22. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. The New England Journal of Medicine 2009, 361(November (20)):1945-1952.